3 results for “Agent Orange and VA Suppression”
The cluster of unexplained chronic symptoms affecting ~25-32% of 1990-91 Gulf War veterans, and the decades-long VA resistance to acknowledging it as a distinct service-connected condition.
The US military's use of Agent Orange herbicide in Vietnam (1961-1971) and the decades-long effort by the VA and chemical manufacturers to deny connections to veteran illnesses — cancers, type 2 diabetes, Parkinson's, peripheral neuropathy.
Claims circulate that pharmaceutical companies or medical institutions suppress Repatha (evolocumab, a PCSK9 inhibitor approved by the FDA in 2015) or effective alternatives to statins. The claim has no documentary basis. Repatha is FDA-approved, actively marketed by Amgen, and available by prescription in more than 60 countries. Its limited uptake relative to statins reflects cost, insurance coverage, and prescribing guidelines — not suppression. Statins remain the first-line standard of care because they are proven, inexpensive, and widely effective; PCSK9 inhibitors are used as second-line or add-on therapy for high-risk patients who cannot tolerate or do not respond adequately to statins.